WO2000072868A3 - Peptides for therapeutic use - Google Patents

Peptides for therapeutic use Download PDF

Info

Publication number
WO2000072868A3
WO2000072868A3 PCT/IB2000/000895 IB0000895W WO0072868A3 WO 2000072868 A3 WO2000072868 A3 WO 2000072868A3 IB 0000895 W IB0000895 W IB 0000895W WO 0072868 A3 WO0072868 A3 WO 0072868A3
Authority
WO
WIPO (PCT)
Prior art keywords
glu
ser
cell protein
compound
clara cell
Prior art date
Application number
PCT/IB2000/000895
Other languages
French (fr)
Other versions
WO2000072868A2 (en
Inventor
Patrick T Prendergast
Original Assignee
Patrick T Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE20000303A external-priority patent/IE20000303A1/en
Application filed by Patrick T Prendergast filed Critical Patrick T Prendergast
Priority to AU58367/00A priority Critical patent/AU5836700A/en
Publication of WO2000072868A2 publication Critical patent/WO2000072868A2/en
Publication of WO2000072868A3 publication Critical patent/WO2000072868A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The peptides have unique effects on the immuno system, resulting in their efficacy in a wide range of syndromes including: viral infections, autoimmune conditions, immune damage and/or disease progression in a patient suffering from one or more autoimmune condition, conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon. This can be achieved through the administration of therapeutic peptides disclosed herein, such as His-His-His-His-His-His-Glu-Ile-Cys-Pro-Ser-Phe-Gln-Arg-Val-Ile-Glu-Thr-Leu-Leu-Met-Asp-Thr-Pro-Ser-Ser-Tyr-Glu-Ala-Ala, or one or more other compound which binds to antibody to Clara Cell protein, or one or more other compound which comprises one or more amino acid sequence which is sufficiently homologous to Clara Cell protein (as defined herein) that the compound provides properties similar to those described herein for Clara Cell protein.
PCT/IB2000/000895 1999-06-01 2000-06-01 Peptides for therapeutic use WO2000072868A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58367/00A AU5836700A (en) 1999-06-01 2000-06-01 Peptides for therapeutic use

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US13722799P 1999-06-01 1999-06-01
US60/137,227 1999-06-01
IE20000170 2000-03-03
IE2000/0170 2000-03-03
IE2000/0303 2000-04-13
IE20000303A IE20000303A1 (en) 2000-04-13 2000-04-13 Peptides for Therapeutic use
IE20000385 2000-05-18
IE2000/0385 2000-05-18
IE2000/0386 2000-05-18
IE20000386 2000-05-18

Publications (2)

Publication Number Publication Date
WO2000072868A2 WO2000072868A2 (en) 2000-12-07
WO2000072868A3 true WO2000072868A3 (en) 2001-12-06

Family

ID=27517569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000895 WO2000072868A2 (en) 1999-06-01 2000-06-01 Peptides for therapeutic use

Country Status (2)

Country Link
AU (1) AU5836700A (en)
WO (1) WO2000072868A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
GB0014870D0 (en) * 2000-06-16 2000-08-09 King S College London Peptides
WO2009043518A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100216722A1 (en) * 2007-09-11 2010-08-26 Dorian Bevec Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent
EP2303308A4 (en) 2008-05-13 2012-11-07 Clarassance Inc Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
HUE030838T2 (en) 2009-10-15 2017-06-28 Therabron Therapeutics Inc Recombinant human cc10 protein for treatment of influenza
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005147A1 (en) * 1987-11-19 1989-06-15 The United States Of America, As Represented By Th New anti-inflammatory agents
EP0617965A1 (en) * 1993-03-15 1994-10-05 Marc Jozef Philemon De Ley Pharmaceutical preparation based on Clara cell protein CC10, and it's use as medicament and diagnosticum
WO2000004863A2 (en) * 1998-07-21 2000-02-03 Claragen, Inc. Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
WO2000062795A2 (en) * 1999-04-21 2000-10-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services The National Institutes Of Health UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005147A1 (en) * 1987-11-19 1989-06-15 The United States Of America, As Represented By Th New anti-inflammatory agents
EP0617965A1 (en) * 1993-03-15 1994-10-05 Marc Jozef Philemon De Ley Pharmaceutical preparation based on Clara cell protein CC10, and it's use as medicament and diagnosticum
WO2000004863A2 (en) * 1998-07-21 2000-02-03 Claragen, Inc. Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
WO2000062795A2 (en) * 1999-04-21 2000-10-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services The National Institutes Of Health UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS

Also Published As

Publication number Publication date
WO2000072868A2 (en) 2000-12-07
AU5836700A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
Ross et al. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
US20060029573A1 (en) Pegylated interferon alpha-1b
AU2926401A (en) Novel chimeric proteins and methods for using the same
CA2348954A1 (en) A pharmaceutical composition for treating immune diseases
CA2326510A1 (en) Dextran formulations and method for treatment of inflammatory joint disorders
ATE415173T1 (en) PAN DR BINDING PROTEINS TO INCREASE THE IMMUNE RESPONSE
AU1179895A (en) Improved interferon polymer conjugates
AU7197096A (en) Peptides of human papilloma virus for use in human T cell response inducing compositions
EP2848627A3 (en) Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
EP2316479A3 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
WO2000072868A3 (en) Peptides for therapeutic use
CN114599665A (en) Compositions, formulations and interleukin production and purification
CA2010275A1 (en) Pancreatic islet cell antigens obtained by molecular cloning
CA2145881A1 (en) Anti-Inflammatory, Tolerogenic and Immunoinhibiting Properties of Carbohydrate Binding-Peptides
ES2144418T3 (en) CELL RECEPTOR PEPTIDES T AS THERAPEUTIC AGENTS FOR DISEASES RELATED TO THE IMMUNE SYSTEM.
WO1993019178A3 (en) Peptides useful for inducing tolerance
GEP20063774B (en) Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
WO1998010787A3 (en) Pharmaceutical compositions for the treatment of immune disorders
AU2005221710A1 (en) Pharmaceutical compositions comprising interferon-tau
Öberg et al. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors
JPH01104021A (en) Composition containing peptide fragment of thrombocyte factor 4 and recovery of inhibition immune response
RU2002128351A (en) APPLICATION OF MIA IN IMMUNOTHERAPY
Vogels et al. Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
Kaplan Delivery of interleukin 2 for immunotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP